基于趋化因子受体4的核医学分子影像在定量评价多发性骨髓瘤肿瘤负荷中的方法学研究

Objective and quantitative evaluation of tumor burden in patients with multiple myeloma is critical to the staging，surveillance and prognosis. The present study aim at the evaluation of tumor mass burden in multiple myeloma with 68Ga-pentixafor PET/CT targeting at CXCR4 in vivo non-invasively and quantitatively. First in preclinical cell lines and models of multiple myeloma, we will validate the specific combination of 68Ga-pentixafor to the tumor tissue. Then establish the measurement of tumor mass according to the 68Ga-pentixafor PET/CT parameters by automatic segmentation procedure，and finally conduct a preliminary clinical investigation to this quantitative assessment of tumor burden in patients with multiple myeloma.

客观而定量地评估多发性骨髓瘤的肿瘤负荷对于肿瘤分期、疗效监测和预后评估有着极其重要的价值。本课题旨在研究针对趋化因子受体4的分子探针--68Ga-pentixafor PET/CT定量评价多发性骨髓瘤肿瘤负荷的方法。首先通过体外组织学如细胞学和动物模型等研究验证多发性骨髓瘤瘤细胞对68Ga-pentixafor摄取的特异性，再进一步通过动物模型研究基于68Ga-pentixafor PET/CT图像参数的定量评估多发性骨髓瘤肿瘤负荷方法，建立计算机模型识别PET/CT图像中的骨髓瘤病灶并筛选全身肿瘤负荷定量参数，最终实现68Ga-pentixafor PET/CT用于定量测定多发性骨髓瘤瘤负荷的初步临床转化。

客观而定量地评估多发性骨髓瘤的肿瘤负荷对于肿瘤分期、疗效监测和预后评估有着极其重要的价值。本课题主要是研究针对趋化因子受体4的分子探针--68Ga-pentixafor PET/CT定量评价多发性骨髓瘤肿瘤负荷的方法。首先通过动物模型实验验证了68Ga-pentixafor评估多发性骨髓瘤瘤瘤负荷的可行性。再进一步通过临床病人显像，借助计算机技术建立了基于68Ga-pentixafor PET/CT骨髓瘤瘤负荷定量检测方法，并筛选全身肿瘤负荷定量参数。结果发现68Ga-Pentixafor PET/CT上的定量指标与终末器官受损、骨髓瘤分期及与瘤负荷相关的实验室指标相关。最终实现68Ga-pentixafor PET/CT用于定量测定多发性骨髓瘤瘤负荷的初步临床转化。